31 August 2012
A research team has identified a potential medical treatment for the cognitive effects of stress-related disorders like post-traumatic stress disorder (PTSD).
The study revealed that an experimental drug called S107 staved off the learning and memory deficits associated with stress-related disorders.
According to the research, which was published in the journal Cell, the drug is one of a new class of small-molecule compounds called Rycals.
A number of previous studies have demonstrated that chronic stress is able to affect the structure and function of neurons in the brain, and researchers have said this could contribute to neuropsychiatric disorders like PTSD.
Study leader Andrew R Marks, noted that the research lends scientists a new insight regarding the mechanism of stress-related cognitive disorders, and has unveiled a possible treatment.
"With the dramatic rise in cases of PTSD among our combat veterans, and following common afflictions such as heart attacks, there is a pressing need for new and better therapies for this debilitating disorder," he said.
Posted by Edward Bartel
Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.